These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 32087003

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT4 receptor partial agonist, in healthy elderly and young subjects.
    Hamatani T, Shibue Y, Sawada N, Takagaki T, Hashimoto M, Nakada Y, Kakuyama H.
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):563-570. PubMed ID: 33189559
    [Abstract] [Full Text] [Related]

  • 3. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
    Hamatani T, Fukudo S, Nakada Y, Inada H, Kazumori K, Miwa H.
    Aliment Pharmacol Ther; 2020 Aug; 52(3):430-441. PubMed ID: 32583907
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
    Meyers NL, Hickling RI.
    J Int Med Res; 2007 Aug; 35(6):848-66. PubMed ID: 18034998
    [Abstract] [Full Text] [Related]

  • 7. DSP-6952, a novel 5-HT4 receptor partial agonist, inhibits visceral hypersensitivity and ameliorates gastrointestinal dysfunction in experimental animals.
    Mine Y, Itakura T, Oku S, Asada R, Shimizu I.
    Eur J Pharmacol; 2018 May 05; 826():123-132. PubMed ID: 29428470
    [Abstract] [Full Text] [Related]

  • 8. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE, Camilleri M, Szarka LA, McKinzie S, Burton D, Thomforde G, Baxter K, Zinsmeister AR.
    Neurogastroenterol Motil; 2007 Oct 05; 19(10):821-30. PubMed ID: 17539894
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats.
    Kii Y, Nakatsuji K, Nose I, Yabuuchi M, Mizuki Y, Ito T.
    Pharmacol Toxicol; 2001 Aug 05; 89(2):96-103. PubMed ID: 11555327
    [Abstract] [Full Text] [Related]

  • 11. Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults.
    Zhao C, Lv Y, Li X, Hou F, Ma X, Wei M, Kang Z, Cui L, Xia Y, Liu Y, Tian J.
    Clin Ther; 2018 Jun 05; 40(6):983-992. PubMed ID: 29803534
    [Abstract] [Full Text] [Related]

  • 12. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
    Hasler WL, Schoenfeld P.
    Drug Saf; 2004 Jun 05; 27(9):619-31. PubMed ID: 15230644
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.
    Toga T, Kohmura Y, Kawatsu R.
    J Pharmacol Sci; 2007 Oct 05; 105(2):207-10. PubMed ID: 17928736
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P.
    Int J Clin Pharmacol Ther; 2012 Aug 05; 50(8):595-604. PubMed ID: 22735462
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.